S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
NYSE:TAK

Takeda Pharmaceutical (TAK) Stock Forecast, Price & News

$15.93
-0.36 (-2.21%)
(As of 09/21/2023 ET)
Compare
Today's Range
$15.92
$16.02
50-Day Range
$15.04
$16.33
52-Week Range
$12.28
$17.15
Volume
1.51 million shs
Average Volume
1.53 million shs
Market Capitalization
$50.41 billion
P/E Ratio
22.13
Dividend Yield
3.20%
Price Target
$21.33

Takeda Pharmaceutical MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
33.9% Upside
$21.33 Price Target
Short Interest
Healthy
0.21% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.28mentions of Takeda Pharmaceutical in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
28.57%
From $0.35 to $0.45 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.80 out of 5 stars

Medical Sector

71st out of 966 stocks

Pharmaceutical Preparations Industry

16th out of 450 stocks


TAK stock logo

About Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, JCR Pharmaceuticals, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

TAK Price History

TAK Stock News Headlines

Takeda Pharmaceutical (OTC: TKPHF)
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
DCGI to keep vigil on sale of 2 drugs
Hereditary Angioedema Therapeutics Global Market Report 2023
Non Hodgkin Lymphoma (NHL) Global Market Report 2023
2 Ultra-Cheap High-Yield Dividend Stocks to Buy Now
Q3 2023 Arrowhead Pharmaceuticals Inc Earnings Call
See More Headlines
Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

TAK Company Calendar

Last Earnings
7/27/2023
Today
9/22/2023
Next Earnings (Estimated)
10/26/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
49,095
Year Founded
1781

Price Target and Rating

Average Stock Price Forecast
$21.33
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+33.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$2.35 billion
Pretax Margin
8.38%

Debt

Sales & Book Value

Annual Sales
$29.81 billion
Cash Flow
$3.51 per share
Book Value
$14.86 per share

Miscellaneous

Outstanding Shares
3,164,690,000
Free Float
3,163,426,000
Market Cap
$50.41 billion
Optionable
Optionable
Beta
0.62

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Christophe Weber (Age 57)
    Pres, CEO & Representative Director
    Comp: $3.93M
  • Mr. Constantine Saroukos (Age 52)
    CFO & Representative Director
    Comp: $2.45M
  • Dr. Andrew S. Plump (Age 58)
    Pres of R&D and Representative Director
    Comp: $2.8M
  • Dr. Seigo Izumo
    Chair of Management Board
  • Mr. Haruhiko Hirate (Age 66)
    Member of Management Board
  • Salvatore Alesci
    Member of Management Board and Head of R&D Global Science & Biomedical Policy
  • Norimasa Takeda
    Chief Accounting Officer & Corp. Controller
  • Mr. Iwaaki Taniguchi
    Sr. VP of Corp. Fin. & Controlling Department
  • Mr. Gabriele Ricci (Age 45)
    Chief Data & Technology Officer
  • Mr. Christopher David O'Reilly
    Global Head of Investor Relations & Global Fin.













TAK Stock - Frequently Asked Questions

Should I buy or sell Takeda Pharmaceutical stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TAK shares.
View TAK analyst ratings
or view top-rated stocks.

What is Takeda Pharmaceutical's stock price forecast for 2023?

2 brokers have issued twelve-month price objectives for Takeda Pharmaceutical's stock. Their TAK share price forecasts range from $14.00 to $30.00. On average, they predict the company's share price to reach $21.33 in the next year. This suggests a possible upside of 33.9% from the stock's current price.
View analysts price targets for TAK
or view top-rated stocks among Wall Street analysts.

How have TAK shares performed in 2023?

Takeda Pharmaceutical's stock was trading at $15.60 on January 1st, 2023. Since then, TAK stock has increased by 2.1% and is now trading at $15.93.
View the best growth stocks for 2023 here
.

When is Takeda Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our TAK earnings forecast
.

How were Takeda Pharmaceutical's earnings last quarter?

Takeda Pharmaceutical Company Limited (NYSE:TAK) announced its quarterly earnings data on Thursday, July, 27th. The company reported $0.55 earnings per share for the quarter. The business earned $7.71 billion during the quarter. Takeda Pharmaceutical had a trailing twelve-month return on equity of 12.54% and a net margin of 7.34%.

What ETFs hold Takeda Pharmaceutical's stock?
Is Takeda Pharmaceutical a good dividend stock?

Takeda Pharmaceutical (NYSE:TAK) pays an annual dividend of $0.51 per share and currently has a dividend yield of 3.11%. The dividend payout ratio is 70.83%. This payout ratio is at a healthy, sustainable level, below 75%. Based on EPS estimates, TAK will have a dividend payout ratio of 113.33% in the coming year. This indicates that the company may not be able to sustain their current dividend.

What guidance has Takeda Pharmaceutical issued on next quarter's earnings?

Takeda Pharmaceutical updated its FY 2023 earnings guidance on Thursday, July, 27th. The company provided earnings per share guidance of $3.16-$3.16 for the period. The company issued revenue guidance of $27.99 billion-$27.99 billion.

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Pfizer (PFE), Verizon Communications (VZ), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), AT&T (T) and Abbott Laboratories (ABT).

What is Takeda Pharmaceutical's stock symbol?

Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."

Who are Takeda Pharmaceutical's major shareholders?

Takeda Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Capital Research Global Investors (0.44%), Goldman Sachs Group Inc. (0.15%), Renaissance Technologies LLC (0.12%), Clal Insurance Enterprises Holdings Ltd (0.09%), BlackRock Inc. (0.08%) and Point72 Asset Management L.P. (0.07%).

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Takeda Pharmaceutical's stock price today?

One share of TAK stock can currently be purchased for approximately $15.93.

How much money does Takeda Pharmaceutical make?

Takeda Pharmaceutical (NYSE:TAK) has a market capitalization of $50.41 billion and generates $29.81 billion in revenue each year. The company earns $2.35 billion in net income (profit) each year or $0.72 on an earnings per share basis.

How many employees does Takeda Pharmaceutical have?

The company employs 49,095 workers across the globe.

Does Takeda Pharmaceutical have any subsidiaries?
The following companies are subsidiares of Takeda Pharmaceutical: ARIAD Pharmaceuticals, Baxalta Manufacturing S.à r.l., IDM Pharma Inc., Intellikine, Inviragen, LigoCyte Pharmaceuticals, Meritage Pharma Inc., Millennium Pharmaceuticals, Millennium Pharmaceuticals Inc., Nihon Pharmaceutical Co. Ltd., Nycomed Pharma, PvP Biologics, Shire, Shire ViroPharma LLC, Takeda (China) Holdings Co. Ltd., Takeda AS, Takeda Austria GmbH, Takeda Bio Development Center, Takeda California Inc., Takeda Consumer Healthcare Company Limited, Takeda Development Center Americas Inc., Takeda Development Center Asia Pte. Ltd., Takeda Development Centre Europe Ltd., Takeda Distribuidora Ltda., Takeda France S.A.S., Takeda GmbH, Takeda Ireland Limited, Takeda Italia S.p.A., Takeda Pharma A/S, Takeda Pharmaceutical (China) Company Limited, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals Korea Co. Ltd., Takeda Pharmaceuticals Limited Liability Company, Takeda Pharmaceuticals U.S.A. Inc., Takeda UK Limited, Takeda Vaccines Inc., Takeda Vaccines Pte. Ltd., and TiGenix.
Read More
How can I contact Takeda Pharmaceutical?

Takeda Pharmaceutical's mailing address is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. The official website for the company is www.takeda.com. The company can be reached via phone at (166) 204-2111, via email at takeda.ir.contact@takeda.com, or via fax at 813-3278-2268.

This page (NYSE:TAK) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -